GeneDx Corp.
WGS | NASDAQ
$89.01
-$8.82 (-9.02%)
Sep 22, 2026, 10:58 AM ET · Market open
Company Profile
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Key Executives
| Name | Position |
|---|---|
| Katherine A. Stueland | Chief Executive Officer & Director |
| Heidi C. Chen | Chief Legal Officer |
| Jami Biliboaca | Chief People Officer |
| Kevin Feeley | Chief Financial Officer |
| Bryan Dechairo | Chief Technology & Innovation Officer |
| Linda Genen | Chief Medical Officer |
| Lisa Gurry | Chief Business Officer |
| Mark A. Gardner | President |
| Melanie Duquette | Chief Growth Officer |
| Sabrina Dunbar | Director of Investor Relations & Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Aug 11, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 03, 2026 | 10-Q | Quarterly Report |
| Aug 03, 2026 | 8-K | Current Report |
| Jul 28, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 21, 2026 | 25-NSE | Filing |
| Jul 01, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
GeneDx Corp.
| Country | United States |
| IPO Date | Nov 3, 2020 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,300 |
| CEO | Katherine A. Stueland |
Contact Details
North Tower Stamford,
Connecticut 06902 United States
Stock Details
| Ticker Symbol | WGS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818331 |
| CUSIP Number | 81663L200 |
| ISIN Number | US81663L2007 |
| SIC Code | 8000 |
Recent News
- 2 days ago / defenseworld.netKevin Feeley Sells 3,728 Shares of GeneDx (NASDAQ:WGS) Stock
- 27 days ago / gurufocus.comGeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors
- 29 days ago / businesswire.comGeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
- 1 month ago / zacks.comCan GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
- 1 month ago / seekingalpha.comGeneDx: Why I Think The Worst Is Behind The Business
- 1 month ago / gurufocus.comIs GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Value Says Overvalued
- 1 month ago / businesswire.comGeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
- 2 months ago / businesswire.comGeneDx to Participate in Upcoming Investor Conferences
- 2 months ago / seekingalpha.comGeneDx Holdings Corp. (WGS) Q2 2026 Earnings Call Transcript
- 2 months ago / marketbeat.comGeneDx Q2 Earnings Call Highlights
Add to Watchlist
Select watchlists to add or remove WGS